LETTER TO EDITOR
Year : 2020 | Volume
: 3 | Issue : 2 | Page : 365-
Authors' reply to Malhotra et al.
Siva Sree Kesana, Venkatraman Radhakrishnan
Department of Medical Oncology, Cancer Institute (W.I.A), Chennai, Tamil Nadu, India
Department of Medical Oncology, Cancer Institute, Adyar, Chennai, Tamil Nadu
|How to cite this article:|
Kesana SS, Radhakrishnan V. Authors' reply to Malhotra et al. Cancer Res Stat Treat 2020;3:365-365
|How to cite this URL:|
Kesana SS, Radhakrishnan V. Authors' reply to Malhotra et al. Cancer Res Stat Treat [serial online] 2020 [cited 2021 Apr 18 ];3:365-365
Available from: https://www.crstonline.com/text.asp?2020/3/2/365/287282
We take this opportunity to thank Malhotra et al. for their kind response and comments on our article, “Clinicopathological characteristics, prognostic factors and outcomes in peripheral T-cell lymphoma: Experience from a single centre in India” and the accompanying editorial.
Twenty-one (14.5%) patients in our study were lost to follow-up, and this was because of socioeconomic reasons and logistics of salvage chemotherapy and autologous stem cell transplantation.
In response to Gupta et al.'s comment on the number of patients who received complete protocol treatment, in our study, out of the total 144 patients diagnosed, 133 were treated with curative intent. Of the 133 patients, 116 were able to complete the intended protocol. Seven patients had Grade 3–4 toxicity, and one patient had a toxic death. Ours being a retrospective study, we expect an underreporting of Grade 3 and 4 toxicities.
We agree that there was a lack of uniformity in the diagnostic criteria and treatment protocols because of the long duration and retrospective nature of the study. We strongly believe that there is a need for evidence-based treatment guidelines and protocols for our population. Moreover, there is also a need for the prospective collection of data on peripheral T-cell lymphomas from various centers in India. The Hematology Cancer Consortium is currently working toward collecting these data prospectively from various centers in India.
Thank you once again for your interest and valuable comments.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
|1||Malhotra H, Gupta N, Bairwa S. Treating lymphomas in low- and middle-income countries. Cancer Res Stat Treat 2020;3:364-5.|
|2||Kesana SS, Ganesan P, Sagar TG, Kannan K, Ganesan TS, Danushkodi M, et al. Clinicopathological characteristics, prognostic factors, and outcomes in peripheral T-cell lymphoma: Experience from a single center in India. Cancer Res Stat Treat. 2020;1:3.|
|3||Jayakar V. T-cell lymphoma: Seeking triumph in the tumult. Cancer Res Stat Treat 2020;3:74.|
|4||Noronha V. Making a case for cancer research in India. Cancer Res Stat Treat 2018;1:71-4.|
|5||Hematology Cancer Consortium of India. Available from: https://www.hemecancer.org/. [Last accessed on 2020 Mar 26].|